Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost For Fayuvi Is Set At $3.95M
https://event.choruscall.com/mediaframe/webcast.html?webcastid=1t78iDYA
Stocks · News reference
Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending
Ultragenyx shares rise after hours following FDA approval of FAYUVI, the first treatment approved for Sanfilippo syndrome Type A.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Ultragenyx Pharmaceutical shares are trading higher after the company announced the FDA approval of FAYUVI for treatment of pediatric patients with mucopolysaccharidosis type IIIA.
8-K filing — Ultragenyx Pharmaceutical Inc. (RARE)
Filed: 2026-09-17 AccNo: 0001515673-26-000006 Size: 146 KB Item 8.01: Other Events